用于单纯疱疹病毒和水痘带状疱疹病毒的在研药物。
Drugs in development for herpes simplex and varicella zoster virus.
机构信息
AiCuris Anti-infective Cures GmbH, Wuppertal, Germany.
出版信息
Clin Pharmacol Ther. 2017 Jul;102(1):30-32. doi: 10.1002/cpt.647. Epub 2017 Mar 17.
DOI:10.1002/cpt.647
PMID:28160282
Abstract
The alpha-herpesviruses varicella zoster virus (VZV) and herpes simplex virus (HSV) share common features including lifelong persistence in sensory ganglia and the risk of recurrences. For both HSV and VZV, standard-of-care (SoC) is based on nucleoside analogs (NAs), which require specific activation in infected cells. These existing drugs exhibit substantial limitations, warranting the development of new and more effective drugs.
摘要
α疱疹病毒水痘带状疱疹病毒（VZV）和单纯疱疹病毒（HSV）具有共同特征，包括在感觉神经节中的终生持续存在和复发的风险。对于 HSV 和 VZV，标准治疗（SoC）基于核苷类似物（NAs），其需要在受感染的细胞中进行特异性激活。这些现有药物存在显著的局限性，需要开发新的更有效的药物。
Zotero 插件